1. Home
  2. OSRH vs HOTH Comparison

OSRH vs HOTH Comparison

Compare OSRH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.54

Market Cap

11.7M

Sector

N/A

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$0.66

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
HOTH
Founded
N/A
2017
Country
United States
United States
Employees
21
3
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
12.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
OSRH
HOTH
Price
$0.54
$0.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
15.2M
3.0M
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.69
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.30
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.49
52 Week High
$1.79
$2.12

Technical Indicators

Market Signals
Indicator
OSRH
HOTH
Relative Strength Index (RSI) 48.45 40.19
Support Level $0.47 $0.49
Resistance Level $0.59 $0.80
Average True Range (ATR) 0.13 0.05
MACD -0.01 -0.00
Stochastic Oscillator 28.38 3.25

Price Performance

Historical Comparison
OSRH
HOTH

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Share on Social Networks: